trending Market Intelligence /marketintelligence/en/news-insights/trending/eKqLcWSLQ3S0uh8rHK88AA2 content esgSubNav
In This List

Dechra Pharmaceuticals adds director

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Dechra Pharmaceuticals adds director

Dechra Pharmaceuticals PLC appointed Lisa Bright to the board as a nonexecutive director, effective Feb. 1, 2019.

Bright serves on the board of Ascendis Pharma A/S and has been president, international, at Intercept Pharmaceuticals Inc. since July 2016. She was also previously a vice president at GlaxoSmithKline PLC and Gilead Sciences Inc.

Northwich, U.K.-based Dechra Pharmaceuticals develops veterinary pharmaceuticals and related products for veterinarians worldwide.